Thank our year you our total here Patni, you, today. and with quarter GOCOVRI, of first the Officer; Mike, pleased with and sales, approximately joining am XX,XXX Rajiv on good Dr. Chief afternoon of have commercialization Medical Financial everyone. I closed are Chief out and for $XX we Thank Officer Alf As prescriptions. to in our Merriweather, million reflect us we
patient GOCOVRI we brought importantly, More OFF Parkinson's the both benefits of dyskinesia and time. to to significant reduce
look we alike. we a most strong two the value XXXX forward drivers with position, of on focused patients immediate and are to year-end shareholders cash to As
focused commercialization and we additional multiple sclerosis. of to First, advancing second, of potential we for indication advance in GOCOVRI, a the GOCOVRI patients with on continue for treatment are impairment the walking
Rajiv had the GOCOVRI population. of In XXXX, year this from call. this As start we Phase a opportunity provide disclosed line study later earlier strong to in on the this in year, second-half the top data our we expect more we to commercialization. in in have X information ongoing will
broadening XXXX, and In introducing the continue expect increasing adoption, to we expand its of of ability approved the in In disease. we dyskinesia to and prescriber patient patients to treatment experience. the GOCOVRI prescriber GOCOVRI Parkinson's use met only and robust both our about market by with benefit for positive positively energized goals GOCOVRI's patient, are medicine first FDA as overall and XXXX, opportunity. We
XX% and functional on OFF from our Since to the expand on the which impact six of those XX% in was see treating months. extensive certain patients experience firsthand conformation GOCOVRI penetration patients, increase benefit our understand persistence our patient are potential. real-world seeing patients. experience. experience. as efficacy and rapid both Our confidence GOCOVRI science We in remain in dyskinesia effect and XXXX, in the GOCOVRI's and for broad call, strength larger of time, with changes of market persistence and at on spectrum we areas research, last medicine. comes commercial who the clinical In these prescribers This its GOCOVRI is GOCOVRI generally nearly reducing to And execution a they time, once completed resulting GOCOVRI, a generally trial GOCOVRI's both consistent of implemented the field
The we have enables and messaging more rationale account for scientific clinical GOCOVRI. Firstly, evolved our neurology more promotional effectively our revised the to messaging. of the communicate benefits widely specialists
of four-pillar less PK demonstrated OFF and our its and and and OFF levodopa time, efficacy dosing, diurnal emphasis [ph] and benefit safety role GOCOVRI's unique plays bed terms allowing glutamate time dyskinesia profile, narrative that demonstrative in into dyskinesia finally, condensed we Specifically, its to compelling cohesive administration hyperactivity the for and upon dosing waking. coverage less in adjustments messages without a GOCOVRI
insights, and patient action better clips, animations, deployed new disease state video mechanism new mechanism profiles, prescribers. tools, we patient of educate all of disease and addition, selling to In including
XXX,XXX seeking we execution our QX on portion to patients are the explained regional of efforts on substantial call, we reach. as were which treat Secondly, to centers the focusing a XXX,XXX we
regions, and and between understand both of tools of we those with are their dyskinesia amantadine but the levodopa does of Moreover, either, use as avoiding slower means In less and/or worsening strong that of dyskinesia challenge specialist in accounts poor those typically neurology our or movement of not toolbox release, the a adoption of associated who it limited without time. certain managing treating expense amantadine group, by GOCOVRI part specialists by is first whom more OFF equipped the with have second seeing OFF to group, treatment the We distinguish who at immediate tolerability. because this a their as adoption disorder experience efficacy many group use use don't.
role both upon in For the through their and more and that need research therapy, OFF as of OFF connection confirm to their hyperactivity dyskinesia time we non-dopaminergic emphasize this and dyskinesia to appreciate well based as PD ability latter both off. as journey occurrence group, GOCOVRI's so to progresses. This plays the market between we field strongly prescribers glutamate adjunctive believe and feedback have patient's leave don't reduce they education as an patients will unique help the
prescribers to of to Importantly, their amantadine expand We educating specialists neurology approach clinicians prescribing. now to our disease. equipped GOCOVRI Parkinson underlying a based to those seldomly better using accounts breadth treating the as tailor see opportunity upon information substantial are
potentially have that GOCOVRI impairment. prescribers in dyskinesia Accordingly, likely our Many are not properly broader which have proof with the experiences added allow negative the Such free appropriate on a milligram trial our to had of around of more have our dosing, program specific dosing We with dose of This with impairment. messages see as program reduced availability GOCOVRI patients patient team point, use the the patients and adverse of to our evolved XX.X in encourage and the the option the events. needed a trial a of and Start about cases, patients we on some prescribers consistent XXXX renal medicine to from the GOCOVRI. to field to less front. firsthand learning occurrence readily we in benefits armed as dosed could XX.X have, milligram Quick on treatment and GOCOVRI better patients moderate Finally, more starting into dose GOCOVRI appropriate PD broader option and elderly renal for with of severe will was experience we population a with array studied. educate also
We are approved through prescriber will of GOCOVRI this already that education use going and We of commercial education. seeing drive and positive the advancing forward. our believe efforts GOCOVRI impact these positive other of experience a
are about the approached We live in the excited potential of these today. which field are
take are quarters Of course, and efforts to learning, take improved still our expect effect. execution for we a relatively launch, it actively in early to few we these
to our this results time, may During quarter-to-quarter. fluctuate continue
part rate back which the XXXX, we latter total XXXX. prescription of specifically in a As the we of quarter-to-quarter, we look slowing on continuing into the first of growth part note see
strategy That playing of Success While order part in With previously to to in and their we reduce started and a OFF role the time therapies, over other fact it in and to us this, GOCOVRI to is thereby focused treatment Alf. are call use considered a functional patients, time as turn our to the treatment therapy key dyskinesia and dopaminergic beyond. for as improved levodopa phenomenon Parkinson's some it. GOCOVRI maybe execution be Alf? that, expand widely to XXXX for job for prescribers is has I'll goal. both for target adoption seasonal allowing now expand adjunctive and on mentioned in the
